ACE, Monoclonal Antibody

Monoclonal ACE; Anti-ACE; Angiotensin Converting Enzyme; CD143

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgM

M4110421

Mouse

Supplied as a liquid in PBS, pH 7.4.

Aliquot and store at -70 degree C or lower. Avoid repeated freeze/thaw cycles

Small volumes of anti-ACE antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Mouse monoclonal ACE antibody

Proteases, Inhibitors, & Enzymes

ELISA, Flow Cytometry (FC/FACS)

84,047 Da

angiotensin I converting enzyme (peptidyl-dipeptidase A) 1

angiotensin-converting enzyme

Angiotensin-converting enzyme

Dcp1; ACE  [Similar Products]

ACE_MOUSE

ACE: Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. Genetic variations in ACE may be a cause of susceptibility to ischemic stroke (ISCHSTR); also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors. Defects in ACE are a cause of renal tubular dysgenesis (RTD). RTD is an autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). Genetic variations in ACE are associated with susceptibility to microvascular complications of diabetes type 3 (MVCD3). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new- onset blindness among diabetic *****s. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Defects in ACE are a cause of susceptibility to intracerebral hemorrhage (ICH). A pathological condition characterized by bleeding into one or both cerebral hemispheres including the basal ganglia and the cerebral cortex. It is often associated with hypertension and craniocerebral trauma. Intracerebral bleeding is a common cause of stroke. Belongs to the peptidase M2 family. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Protease; Membrane protein, integral; EC 3.4.15.1

Cellular Component: extracellular space; membrane; lysosome; brush border membrane; cytoplasm; extracellular region; integral to membrane; plasma membrane; basal plasma membrane; vesicle; endosome; external side of plasma membrane

Molecular Function: tripeptidyl-peptidase activity; peptidyl-dipeptidase activity; hydrolase activity; carboxypeptidase activity; zinc ion binding; metallopeptidase activity; mitogen-activated protein kinase kinase binding; metal ion binding; mannosyl-oligosaccharide mannosidase activity; drug binding; actin binding; glucosidase activity; trehalase activity; peptidase activity; protein binding; fucosidase activity; galactosidase activity; lytic transglycosylase activity; hexosaminidase activity; endopeptidase activity; bradykinin receptor binding; exopeptidase activity; mitogen-activated protein kinase binding; amylase activity; mannosidase activity; chloride ion binding

Biological Process: positive regulation of protein binding; positive regulation of apoptosis; neutrophil mediated immunity; positive regulation of systemic arterial blood pressure; response to lipopolysaccharide; regulation of angiotensin metabolic process; proteolysis; sensory perception of pain; regulation of smooth muscle cell migration; peptide metabolic process; beta-amyloid metabolic process; peptide catabolic process; regulation of blood pressure; kidney development; negative regulation of protein binding; vasoconstriction; organ regeneration; positive regulation of neurogenesis; eating behavior; arachidonic acid secretion; regulation of systemic arterial blood pressure by renin-angiotensin; heart contraction; hormone catabolic process; spermatogenesis; alveolus development; positive regulation of inflammatory response

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.